Rezolute announces positive study results for rz402, an oral pki being developed for dme

Phase 2 proof-of-concept study anticipated in 2h 2022 phase 2 proof-of-concept study anticipated in 2h 2022

RZLT Ratings Summary

RZLT Quant Ranking